drugset / Trial / NCT05445804
Oral Cannabidiol for Tobacco Cessation
Phase 1
Recruiting
50 enrolled
Johns Hopkins University
National Institute on Drug Abuse (NIDA) · collab
RandomizedCrossoverTriple-blindBasic science
Summary
Cannabidiol is a compound found in cannabis plants that is well tolerated, has low abuse liability, and might be an effective medication to promote tobacco cessation. This clinical study will use a validated approach for screening tobacco cessation medications to determine if oral cannabidiol increases short-term tobacco abstinence, and evaluate mechanisms that might explain how cannabidiol alters smoking behavior. Results from this study will provide data on the therapeutic potential of cannabidiol for tobacco cessation.
Timeline
- Start
- 2022-11-01
- Primary completion
- 2026-12-01
- Completion
- 2027-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cannabidiol | Other / unclassified | 300 mg | Oral |
| Subject | Cannabidiol | Other / unclassified | 600 mg | Oral |